- Home
- FSP vs PBYI Comparison
FSP vs PBYI Comparison
Compare FSP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- PBYI
- Stock Information
- Founded
- FSP 1981
- PBYI 2010
- Country
- FSP United States
- PBYI United States
- Employees
- FSP N/A
- PBYI N/A
- Industry
- FSP Real Estate Investment Trusts
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- PBYI Health Care
- Exchange
- FSP Nasdaq
- PBYI Nasdaq
- Market Cap
- FSP 159.5M
- PBYI 138.4M
- IPO Year
- FSP N/A
- PBYI N/A
- Fundamental
- Price
- FSP $1.53
- PBYI $2.91
- Analyst Decision
- FSP
- PBYI Strong Buy
- Analyst Count
- FSP 0
- PBYI 1
- Target Price
- FSP N/A
- PBYI $7.00
- AVG Volume (30 Days)
- FSP 285.2K
- PBYI 280.0K
- Earning Date
- FSP 04-29-2025
- PBYI 05-08-2025
- Dividend Yield
- FSP 2.65%
- PBYI N/A
- EPS Growth
- FSP N/A
- PBYI 143.51
- EPS
- FSP N/A
- PBYI 0.77
- Revenue
- FSP $115,994,000.00
- PBYI $232,668,000.00
- Revenue This Year
- FSP $4.36
- PBYI N/A
- Revenue Next Year
- FSP $0.81
- PBYI N/A
- P/E Ratio
- FSP N/A
- PBYI $3.78
- Revenue Growth
- FSP N/A
- PBYI 2.67
- 52 Week Low
- FSP $1.36
- PBYI $2.23
- 52 Week High
- FSP $2.21
- PBYI $5.20
- Technical
- Relative Strength Index (RSI)
- FSP 43.75
- PBYI 44.50
- Support Level
- FSP $1.49
- PBYI $2.88
- Resistance Level
- FSP $1.60
- PBYI $3.14
- Average True Range (ATR)
- FSP 0.07
- PBYI 0.16
- MACD
- FSP 0.01
- PBYI 0.00
- Stochastic Oscillator
- FSP 28.12
- PBYI 11.36
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.